8-K: Surgery Partners Shareholders Re-Elect Directors, Approve Exec Pay

Surgery Partners, Inc. announced the results of its Annual Meeting, confirming the re-election of Class II directors and the approval of executive compensation and auditor ratification.

Summary

• Shareholders re-elected all three Class II director nominees: Devin O'Reilly, Brent Turner, and Laura L. Forese, M.D., to serve until the 2029 annual meeting.
• The advisory vote on executive compensation for named executive officers was approved on a non-binding basis, with 111,639,092 votes for, 2,018,777 votes against, and 15,275 abstentions.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 was ratified, with 119,828,741 votes for, 62,950 votes against, and 24,648 abstentions.
• As of the record date, April 8, 2026, 130,798,102 shares of common stock were outstanding and entitled to vote.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive outcome, reflecting stable corporate governance and shareholder support for the current board and executive compensation, despite some dissent in director re-elections.

Positives

• All three Class II director nominees were successfully re-elected, ensuring continuity in board leadership.
• The advisory vote on executive compensation passed with a strong majority, indicating shareholder support for the company's current compensation practices.
• The ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026 passed overwhelmingly, reflecting confidence in the company's financial oversight.

Negatives

• Devin O'Reilly and Laura L. Forese, M.D. received a notable number of 'Votes Withheld' (23,613,725 and 22,551,367 respectively) compared to Brent Turner (3,525,262), suggesting some level of shareholder dissent or concern regarding these specific directors, although not enough to prevent their re-election.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing beyond the re-elected directors serving until the 2029 annual meeting.

Industry Context

StockSavvy.ai notes that routine annual meeting results, such as director re-elections and auditor ratification, are standard corporate governance practices across the healthcare services industry. The advisory vote on executive compensation reflects ongoing shareholder engagement on pay practices, a common theme in public companies.

Comparison to Industry Standards

• Routine annual meeting votes typically see high approval rates for management-backed proposals. The approval rates for Surgery Partners' proposals are generally in line with industry averages for similar votes, indicating stable shareholder support for current governance and compensation structures.
• While director re-elections often pass with high majorities, the level of 'votes withheld' for certain directors can sometimes be higher than the industry average for uncontested elections, potentially signaling minor shareholder concerns.

Corporate Governance

Stakeholder Impact

• Shareholders demonstrated support for the current board and executive compensation, indicating confidence in the company's leadership and governance.
• The re-election of directors ensures continuity in strategic oversight, which can provide stability for employees and business partners.

Next Steps

• The re-elected Class II directors will serve until the Company's 2029 annual meeting of stockholders.

Key Dates

Recommendation

The filing indicates stable corporate governance with all proposals passing as expected. There are no new financial or operational details to warrant a change in investment thesis, suggesting a 'hold' position for existing investors.

Keywords

Surgery Partners, SGRY, Annual Meeting, Shareholder Vote, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance